$62.58
0.38%
Downside
Day's Volatility :0.86%
Upside
0.48%
0.42%
Downside
52 Weeks Volatility :27.78%
Upside
27.48%
Period | Incyte Corporation | |
---|---|---|
3 Months | -18.23% | |
6 Months | -19.51% | |
1 Year | -17.45% | |
3 Years | -37.7% |
Market Capitalization | 14.0B |
Book Value | $20.01 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 1.43 |
PE Ratio | 43.97 |
PEG Ratio | 0.47 |
Wall Street Target Price | 82.24 |
Profit Margin | 9.35% |
Operating Margin TTM | 14.47% |
Return On Assets TTM | 5.78% |
Return On Equity TTM | 7.79% |
Revenue TTM | 3.5B |
Revenue Per Share TTM | 15.6 |
Quarterly Revenue Growth YOY | 10.299999999999999% |
Gross Profit TTM | 1.6B |
EBITDA | 575.7M |
Diluted Eps TTM | 1.43 |
Quarterly Earnings Growth YOY | -0.43 |
EPS Estimate Current Year | 3.4 |
EPS Estimate Next Year | 4.69 |
EPS Estimate Current Quarter | 0.75 |
EPS Estimate Next Quarter | 0.91 |
What analysts predicted
Upside of 31.42%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 38.93% |
Net Income | -313.1M | ↓ 400.46% |
Net Profit Margin | -20.38% | ↓ 29.81% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | ↑ 22.5% |
Net Income | 109.5M | ↓ 134.97% |
Net Profit Margin | 5.82% | ↑ 26.2% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.2B | ↑ 14.71% |
Net Income | 446.9M | ↑ 308.16% |
Net Profit Margin | 20.7% | ↑ 14.88% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.7B | ↑ 23.53% |
Net Income | -295.7M | ↓ 166.17% |
Net Profit Margin | -11.09% | ↓ 31.79% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.0B | ↑ 11.98% |
Net Income | 948.6M | ↓ 420.79% |
Net Profit Margin | 31.76% | ↑ 42.85% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.4B | ↑ 13.67% |
Net Income | 340.7M | ↓ 64.09% |
Net Profit Margin | 10.04% | ↓ 21.72% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 862.9M | ↑ 6.13% |
Net Income | 563.9M | ↑ 210.25% |
Net Profit Margin | 65.35% | ↑ 43.0% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 733.2M | ↓ 15.02% |
Net Income | 38.0M | ↓ 93.26% |
Net Profit Margin | 5.18% | ↓ 60.17% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 911.4M | ↑ 24.3% |
Net Income | 161.4M | ↑ 324.91% |
Net Profit Margin | 17.71% | ↑ 12.53% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 823.3M | ↓ 9.67% |
Net Income | 112.8M | ↓ 30.14% |
Net Profit Margin | 13.7% | ↓ 4.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 926.7M | ↑ 12.56% |
Net Income | 28.5M | ↓ 74.76% |
Net Profit Margin | 3.07% | ↓ 10.63% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 17.9M | ↓ 98.07% |
Net Income | 1000.0K | ↓ 96.49% |
Net Profit Margin | 5.59% | ↑ 2.52% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 40.52% |
Total Liabilities | 672.0M | ↓ 44.88% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↑ 14.9% |
Total Liabilities | 719.8M | ↑ 7.12% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.4B | ↑ 29.52% |
Total Liabilities | 828.3M | ↑ 15.08% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.6B | ↑ 3.92% |
Total Liabilities | 949.7M | ↑ 14.64% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 4.9B | ↑ 38.54% |
Total Liabilities | 1.2B | ↑ 22.5% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 5.8B | ↑ 18.4% |
Total Liabilities | 1.5B | ↑ 26.43% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 4.9B | ↑ 17.49% |
Total Liabilities | 1.2B | ↑ 10.78% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.1B | ↑ 2.45% |
Total Liabilities | 1.2B | ↑ 2.39% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.3B | ↑ 5.24% |
Total Liabilities | 1.2B | ↑ 3.6% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.5B | ↑ 3.59% |
Total Liabilities | 1.3B | ↑ 4.02% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.8B | ↑ 6.0% |
Total Liabilities | 1.5B | ↑ 14.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 79.6M | ↓ 98.64% |
Total Liabilities | 33.3M | ↓ 97.74% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -93.0M | ↓ 130.51% |
Investing Cash Flow | -350.0M | ↑ 50.54% |
Financing Cash Flow | 690.2M | ↑ 1076.86% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 336.2M | ↓ 461.58% |
Investing Cash Flow | -86.4M | ↓ 75.31% |
Financing Cash Flow | 14.7M | ↓ 97.88% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 710.7M | ↑ 111.36% |
Investing Cash Flow | -87.5M | ↑ 1.19% |
Financing Cash Flow | 45.7M | ↑ 211.87% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -124.6M | ↓ 117.53% |
Investing Cash Flow | -269.0M | ↑ 207.59% |
Financing Cash Flow | 71.7M | ↑ 56.87% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 749.5M | ↓ 701.52% |
Investing Cash Flow | -207.7M | ↓ 22.79% |
Financing Cash Flow | 6.2M | ↓ 91.39% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 969.9M | ↑ 29.41% |
Investing Cash Flow | -78.5M | ↓ 62.18% |
Financing Cash Flow | -794.0K | ↓ 112.86% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 115.4M | ↓ 54.78% |
Investing Cash Flow | -66.0M | ↑ 101.65% |
Financing Cash Flow | 9.0M | ↓ 146.55% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 215.7M | ↑ 87.03% |
Investing Cash Flow | -16.7M | ↓ 74.64% |
Financing Cash Flow | 96.0K | ↓ 98.93% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 174.2M | ↓ 19.27% |
Investing Cash Flow | -12.5M | ↓ 25.48% |
Financing Cash Flow | 15.9M | ↑ 16463.54% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 296.4M | ↑ 70.18% |
Investing Cash Flow | -28.4M | ↑ 127.58% |
Financing Cash Flow | -14.3M | ↓ 190.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 283.7M | ↓ 4.29% |
Investing Cash Flow | -20.9M | ↓ 26.37% |
Financing Cash Flow | -2.5M | ↓ 82.67% |
Sell
Neutral
Buy
Incyte Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Baker Bros Advisors LP
Vanguard Group Inc
BlackRock Inc
Dodge & Cox
Royal Bank of Canada
State Street Corporation
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.
Organization | Incyte Corporation |
Employees | 2324 |
CEO | Mr. Herve Hoppenot |
Industry | Health Technology |
Biogen Inc.
$298.66
+0.51%
IQVIA Holdings Inc.
$199.45
+1.0%
Cigna Corp.
$244.10
-1.2%
Mettler-Toledo International Inc.
$1,348.19
+2.37%
AmerisourceBergen Corp.
$168.41
-1.03%
GE HEALTHCARE TECHNOLOGIES INC.
$78.43
-1.79%
Edwards Lifesciences Corp.
$82.01
+0.44%
BioMarin Pharmaceutical Inc.
$88.49
-0.28%
Zimmer Biomet Holdings, Inc.
$127.65
-0.12%